Visceral Adipose Tissue Research
Tesamorelin is among the most studied GHRH analogues for visceral fat reduction. Preclinical and clinical research has documented significant reductions in trunk fat accumulation in models of GH-axis insufficiency.
Overview
What is Tesamorelin?
Tesamorelin is a stabilized synthetic analogue of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus. Research has examined its effects on visceral adipose tissue reduction, GH/IGF-1 axis stimulation, and lipid metabolism in animal and clinical models.
Tesamorelin (Trans-3-hexenoic acid-GRF(1-44)-NH₂) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.
Investigational Scope
Documented Research Areas
The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.
GH/IGF-1 Axis Stimulation
Research has characterized Tesamorelin as a potent stimulator of pulsatile GH release, with studies documenting robust IGF-1 elevations in treated animal and human subjects across multiple research settings.
Lipid Metabolism Models
Studies have examined Tesamorelin's effects on triglyceride levels, HDL/LDL ratios, and hepatic lipid metabolism in animal models of dyslipidemia, with observed improvements in lipid profile markers.
CNS & Cognitive Function Models
Research has examined Tesamorelin's effects on cognitive function in aged animal models, with studies suggesting GH/IGF-1 axis restoration may support hippocampal-dependent memory and learning parameters.
Proposed Mechanism
Mechanistic Pathway
Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.
-
1
GHRH Receptor Full Agonism
Tesamorelin is a full agonist at the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion through the same pathway as endogenous GHRH.
-
2
N-Terminal Stabilization
The trans-3-hexenoic acid modification at the N-terminus protects Tesamorelin from rapid degradation by dipeptidyl peptidase IV (DPP-IV), significantly extending its biological half-life compared to native GHRH.
-
3
Lipolytic Pathway Activation
GH released in response to Tesamorelin activates hormone-sensitive lipase and promotes lipolysis in visceral adipocytes. Research has documented preferential visceral fat mobilization compared to subcutaneous depots.
-
4
IGF-1 Mediated Metabolic Effects
Downstream IGF-1 elevation following Tesamorelin-stimulated GH release mediates protein anabolic effects and insulin sensitization in muscle tissue, documented across multiple animal and clinical study models.
Technical Data
Molecular Specifications
| Amino Acid Sequence | Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ |
|---|---|
| Molecular Weight | 5,135.8 g/mol |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| CAS Number | 218949-48-5 |
| Storage | −20°C long-term, 4°C short-term up to 4 weeks |
References
Selected Literature
The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.
- Stanley TL, et al. (2012). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV-infected patients: a randomised, double-blind, multicentre trial. Lancet HIV, 2(10), e427–e436.
- Falutz J, et al. (2010). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 24(14), 2251–2260.
- Dhillon S. (2011). Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 71(8), 1071–1091.
- Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
- Clemmons DR. (2011). Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. Journal of Clinical Endocrinology & Metabolism, 88(11), 4759–4767.
Research Disclaimer
This product is intended strictly for laboratory research purposes only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or animal consumption. All information presented is derived from published scientific literature and is provided for educational reference only. By purchasing, the buyer affirms they are a qualified researcher or institution and assume full responsibility for the safe and lawful handling of this material.